Altogether, the clinical and therapeutic importance of the CIP2A/AKT axis as well as the relevance of CIP2A as a key AKT regulator and plausible molecular target in breast cancer must be fully clarified, which represents our main objective in this study. The gene discussed is AKT1; the disease is breast carcinoma.